A multicentered , randomized , open study on efficacy and safety of Meifute ® antifungal solution of optimal application time in moccasin-type tinea pedis

Objective: This study aimed to evaluate the efficacy and safety of the Meifute® antifungal solution on moccasin-type tinea pedis with optimal application time. Methods: A multicentered, randomized and open clinical trial was conducted by enrolling 267 patients with moccasin-type tinea pedis from 10 centers. 91 of these patients were treated with regimen A (foot bath twice per 7 days, 2 hours each time), 87 with regimen B (foot bath twice per 7 days, 1 hour each time) and 89 with regimen C (foot bath twice per 7 days, 0.5 hour each time). The evaluation of mycological effect, clinical efficacy and the overall therapeutic effect were achieved using fungus microscopic examination, fungus culture method and total symptom score. The initial valuation data were recorded as the baseline and further data were collected 1 week after the first administration (V1), 1 week after the second administration (V2) and 2 weeks after the withdrawal (V3). Results: At V3, the number of eligible patients in group A, B and C were 69, 78 and 80, respectively. There was no statistically significant difference in the fungal clearance rates (84.1%, 88.5% and 76.3%, respectively), clinical effective rate (14.5%, 28.2% and 24.1%, respectively) or integral effective rate (49.3%, 61.5% and 56.3%, respectively) among three groups. The adverse events including transient pain (31 cases, 11.6%), pain (20 cases, 7.5%), erosion (17 cases, 6.4%), pruritus (10 cases, 3.7%), burning (6 cases, 2.2%) and swelling (3 cases, 1.1%) be alleviated without any treatment. The incidence of pain and erosion in group A was significantly higher than that in group B and C. The only case of ulcer happened in group A which was cured after one-week application of Bactroban, Bifonazole, and Hirudoid. Because of the different incident of adverse reactions, there were significant difference in the dropout rates among group A, B and C (9.9%, 2.3% and 0.0%, respectively). Conclusion: The therapeutic efficacy of a 0.5 h treatment with antifungal liquid was found to be the same as that of standard application time of 2 hours. On the other hand, 0.5 h treatment protocol could reduce the incidence of adverse reactions and therefore improve the compliance of patients.

[1]  A. M. Reis,et al.  Adverse Drug Reactions in Patients Receiving Systemic Antifungal Therapy at a High‐Complexity Hospital , 2016, Journal of clinical pharmacology.

[2]  T. Vlahovic The Role of Naftifine HCl 2% Gel and Cream in Treating Moccasin Tinea Pedis. , 2016, Journal of drugs in dermatology : JDD.

[3]  Y. Tsunemi Oral Antifungal Drugs in the Treatment of Dermatomycosis. , 2016, Medical mycology journal.

[4]  Y. Ran,et al.  Administration of Oral Itraconazole Capsule with Whole Milk Shows Enhanced Efficacy As Supported by Scanning Electron Microscopy in a Child with Tinea Capitis Due to Microsporum canis , 2015, Pediatric dermatology.

[5]  A. Fleischer,et al.  Naftifine Hydrochloride Gel 2%: An Effective Topical Treatment for Moccasin-Type Tinea Pedis. , 2015, Journal of drugs in dermatology : JDD.

[6]  M. Ilkit,et al.  Tinea pedis: The etiology and global epidemiology of a common fungal infection , 2015, Critical reviews in microbiology.

[7]  Y. Zou,et al.  Efficacy and Safety of Fluocinolone Acetonide, Hydroquinone, and Tretinoin Cream in Chinese Patients with Melasma: A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Parallel-Group Study , 2015, Clinical Drug Investigation.

[8]  B. Shah,et al.  Development of self emulsifying drug delivery system of itraconazole for oral delivery: formulation and pharmacokinetic consideration , 2015, Journal of Pharmaceutical Investigation.

[9]  Y. Ran,et al.  Successful treatment of oral itraconazole for infantile hemangiomas: A case series , 2015, The Journal of dermatology.

[10]  J. Ely,et al.  Diagnosis and management of tinea infections. , 2014, American family physician.

[11]  B. Ahishali,et al.  Ultrastructural Alterations In The Epidermis Of Patients With Tinea Pedis , 2009 .

[12]  T. Kurth,et al.  The safety of oral antifungal treatments for superficial dermatophytosis and onychomycosis: a meta-analysis. , 2007, The American journal of medicine.

[13]  J. Castellsagué,et al.  Risk of serious skin disorders among users of oral antifungals: a population-based study , 2002, BMC dermatology.

[14]  K. Katsuoka,et al.  Bifonazole (Mycospor® cream) in the treatment of moccasin‐type tinea pedis. Comparison between combination therapy of bifonazole cream +10% urea ointment (Urepearl®) and occlusive dressing therapy with the same agents , 2000, Mycoses.

[15]  S. Nishiyama,et al.  Clinical evaluation of bifonazole for moccasin‐type tinea pedis , 1997, Mycoses.

[16]  R. Savin Terbinafine (Lamisil) versus griseofulvin in moccasin type tinea pedis , 1990 .

[17]  D. Greer Topical treatment for moccasin-type tinea pedis. , 1987, Journal of the American Academy of Dermatology.